BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Down – Here’s What Happened

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) gapped down before the market opened on Tuesday . The stock had previously closed at $7.46, but opened at $7.23. BioCryst Pharmaceuticals shares last traded at $7.43, with a volume of 67,628 shares trading hands.

Analyst Ratings Changes

A number of research analysts have recently issued reports on BCRX shares. Royal Bank of Canada restated an “outperform” rating and issued a $10.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday, November 5th. Barclays raised their target price on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 5th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $14.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday, November 5th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $15.60.

BioCryst Pharmaceuticals Stock Performance

The stock has a market cap of $1.51 billion, a price-to-earnings ratio of -11.98 and a beta of 1.79. The company’s 50 day simple moving average is $7.62 and its 200 day simple moving average is $7.42.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its earnings results on Monday, November 4th. The biotechnology company reported ($0.07) EPS for the quarter, hitting the consensus estimate of ($0.07). The firm had revenue of $117.10 million for the quarter, compared to the consensus estimate of $113.99 million. BioCryst Pharmaceuticals’s revenue for the quarter was up 35.1% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.19) EPS. Sell-side analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.38 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of BCRX. Deerfield Management Company L.P. Series C lifted its holdings in shares of BioCryst Pharmaceuticals by 62.9% during the second quarter. Deerfield Management Company L.P. Series C now owns 8,135,804 shares of the biotechnology company’s stock valued at $50,279,000 after purchasing an additional 3,140,804 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of BioCryst Pharmaceuticals by 2.7% in the third quarter. Geode Capital Management LLC now owns 4,837,985 shares of the biotechnology company’s stock worth $36,776,000 after buying an additional 127,708 shares during the period. Fisher Asset Management LLC increased its position in shares of BioCryst Pharmaceuticals by 16.9% in the third quarter. Fisher Asset Management LLC now owns 3,338,062 shares of the biotechnology company’s stock worth $25,369,000 after acquiring an additional 481,359 shares in the last quarter. Two Sigma Advisers LP raised its holdings in shares of BioCryst Pharmaceuticals by 13.6% during the third quarter. Two Sigma Advisers LP now owns 2,181,012 shares of the biotechnology company’s stock valued at $16,576,000 after acquiring an additional 261,500 shares during the period. Finally, Rice Hall James & Associates LLC lifted its position in shares of BioCryst Pharmaceuticals by 4.0% in the 3rd quarter. Rice Hall James & Associates LLC now owns 2,163,743 shares of the biotechnology company’s stock valued at $16,444,000 after acquiring an additional 84,102 shares in the last quarter. Institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.